the ADBL report

Issue #121, July 2021

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 17, 2021. The Committee reviewed Manufacturer submissions for twenty-five (25) Drug Products for potential listing, or change in listing, on the *ADBL*.

In addition to Drug Products reviewed by the Expert Committee, thirty-three (33) Drug Products underwent Expedited Review for listing on the *ADBL* effective June 1, 2021, and twenty-one (21) Drug Products underwent Expedited Review for listing on the *ADBL* effective July 1, 2021.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Product was reviewed by CDR and the Expert Committee and added to the *ADBL* effective July 1, 2021:

- **OLUMIANT* 2 mg tablet** (baricitinib) (LIL) via Special Authorization (SA)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of New IC Groupings, effective July 1, 2021:

- **METHOTREXATE (PRESERVED) 25 mg/mL injection BP** (methotrexate sodium) (AHI)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2021)

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Products were added to the *ADBL* effective July 1, 2021:

- **INCLUNOX 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL & 100 mg/1 mL injection syringes, & INCLUNOX HP 120 mg/0.8 mL & 150 mg/mL injection syringes** (enoxaparin sodium) (SDZ)
- **REDESCA 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL & 100 mg/mL injection syringes, 300 mg/3 mL injection vial, & REDESCA HP 120 mg/0.8 mL & 150 mg/mL injection syringes** (enoxaparin sodium) (VLP)

Change of Listing Status

The benefit listing status of the following Drug Products have been changed from Regular Benefits to Restricted Benefits effective July 1, 2021:

- **LOVENOX* 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL & 120 mg/0.8 mL injection syringes & 100 mg/mL vial & LOVENOX HP 150 mg/mL injection syringe** (enoxaparin sodium) (SAV) via Restricted Benefit